FDA Approves Jemperli for Rectal Cancer, Offering Some Patients a Chance to Avoid Surgery and Chemotherapy
U.S. Food and Drug Administration (FDA) has granted accelerated approval to Jemperli (dostarlimab-gxly) as a standalone treatment for certain adults with previously untreated stage II or stage III locally advanced rectal cancer, potentially allowing them to avoid surgery, radiation and chemotherapy.
